Age-Related Macular Degeneration Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments - Research and Markets

DUBLIN--()--The "Age-Related Macular Degeneration Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments" report has been added to Research and Markets' offering.

The global age-related macular degeneration market accounted for revenue of $5,335.7 million in 2015, and it is expected to grow at a CAGR of 7.6% during 2016 - 2022.

Among the various types, the wet AMD segment is expected to witness the faster growth during the forecast period.

The global age-related macular degeneration market is growing at a significant rate, due to growing geriatric population, and increasing prevalence of age-related macular degeneration.

In addition, increasing prevalence of lifestyle associated diseases such as obesity and hypertension, increasing healthcare expenditure and increasing pipeline drugs for AMD are also driving the growth of the global age-related macular degeneration market.

Age-related macular degeneration (AMD) is an acquired retinal disorder indicated by fundus changes. It is one of the most common forms of visual impairment in the geriatric population.

It is a deterioration or degeneration of macular, leading to vision loss among people aged 60 years and above. The macula is a small part of retina responsible of sharpness and central vision.

Key Topics Covered:

1. Research Scope And Methodology

2. Executive Summary

3. Market Outlook

4. Drug Approval Process In The U.S. And Eu

5. Global Age-Related Macular Degeneration Market Size And Forecast (2012-2022)

6. Global Age-Related Macular Degeneration Market, By Type

7. Global Age-Related Macular Degeneration Market, By Geography

8. Competitive Positioning Analysis

9 Key Company Profiles

  • Novartis Ag
  • F. Hoffmann-La Roche Ltd
  • Bayer Ag.
  • Regeneron Pharmaceutical, Inc.
  • Acucela
  • Ophthotech Corporation
  • Neurotech Pharmaceuticals, Inc.
  • Glaxosmithkline Plc
  • Stemcells Inc.
  • Alimera Sciences, Inc.

10. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/3fqkl5/agerelated

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Clinical Trials, Optical Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Clinical Trials, Optical Disorders Drugs